Ray M.
- Country
- Ireland
- Department
- Oncology
Research Overview
- A Randomized Controlled Trial Evaluating the Efficacy of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving Androgen Deprivation Therapy
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Data & Insights
Has run more than one trial at 293 of 550 partner sites.
Specializations
Advanced Solid Tumor Oncology
Focus on metastatic and high‑risk solid tumors across multiple organ systems, spanning adjuvant to refractory disease stages.
- Metastatic prostate cancer
- Advanced renal cell carcinoma
- Advanced non‑small cell lung cancer
- Advanced breast cancer
- Advanced urothelial carcinoma
- Advanced colorectal cancer
- Advanced gastric cancer
- Advanced pancreatic adenocarcinoma
- Advanced melanoma
- Advanced bladder cancer
Investigations address disease‑free survival, overall survival, and biomarker‑guided therapeutic stratification.
Hematologic Malignancies
Research spanning acute, chronic, and lymphoid neoplasms with emphasis on novel targeted and immunologic approaches.
- Acute myeloid leukemia
- Diffuse large B‑cell lymphoma
- Newly diagnosed multiple myeloma
- Myelodysplastic syndromes
- Treatment‑naïve chronic lymphocytic leukemia
Efforts include evaluation of disease‑specific survival endpoints and integration of molecular profiling.
Immunotherapy and Targeted Therapeutics
Development of checkpoint inhibition, kinase inhibition, and biomarker‑directed strategies across tumor types.
- PD‑1/PD‑L1 checkpoint inhibition
- KRAS G12C targeted therapy
- HER2‑directed therapy
- FGFR‑targeted agents
- CDK4/6 inhibition
- PARP inhibition
- CTLA‑4 blockade
Combination regimens with chemotherapy or radiation are evaluated for synergistic efficacy.
Respiratory and Pulmonary Disorders
Clinical investigations targeting chronic airway and interstitial lung diseases to reduce exacerbations and improve function.
- Severe asthma
- Chronic obstructive pulmonary disease
- Idiopathic pulmonary fibrosis
- Autoimmune pulmonary alveolar proteinosis
- Bronchiectasis
Endpoints include rate of moderate‑to‑severe exacerbations and preservation of lung capacity.
Neurodegenerative and Cognitive Disorders
Studies aiming to modify disease trajectory and preserve cognition in Alzheimer‑related conditions.
- Dominantly inherited Alzheimer disease
- Mild cognitive impairment
- Alzheimer’s‑type dementia
- Early Alzheimer’s disease
- Down syndrome‑associated Alzheimer’s disease
Assessments focus on cognitive rating scales and biomarkers of neurodegeneration.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
